Display options
Cite
Danilov AV, Spurgeon SE, Siddiqi T, et al. A phase Ib, open label, dose escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia. Invest New Drugs. 2021;39(4):1099-1105doi: 10.1007/s10637-020-01056-4.
Danilov, A. V., Spurgeon, S. E., Siddiqi, T., Quinson, A. M., Maier, D., Smith, D., & Brown, J. R. (2021). A phase Ib, open label, dose escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia. Investigational new drugs, 39(4), 1099-1105. https://doi.org/10.1007/s10637-020-01056-4
Danilov, Alexey V, et al. "A phase Ib, open label, dose escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia." Investigational new drugs vol. 39,4 (2021): 1099-1105. doi: https://doi.org/10.1007/s10637-020-01056-4
Danilov AV, Spurgeon SE, Siddiqi T, Quinson AM, Maier D, Smith D, Brown JR. A phase Ib, open label, dose escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia. Invest New Drugs. 2021 Aug;39(4):1099-1105. doi: 10.1007/s10637-020-01056-4. Epub 2021 Mar 08. PMID: 33683501; PMCID: PMC8279974.
Copy Download .nbib Format: NLM
Share it on

Invest New Drugs. 2021 Aug;39(4):1099-1105. doi: 10.1007/s10637-020-01056-4. Epub 2021 Mar 08.

A phase Ib, open label, dose escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia.

Investigational new drugs

Alexey V Danilov, Stephen E Spurgeon, Tanya Siddiqi, Anne-Marie Quinson, Daniela Maier, Dionne Smith, Jennifer R Brown

Affiliations

  1. City Of Hope National Medical Center, Duarte, CA, USA.
  2. Knight Cancer Institute at Oregon Health & Science University, Portland, OR, USA.
  3. Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany.
  4. Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, CT, USA.
  5. Dana-Farber Cancer Institute, Boston, MA, USA. [email protected].

PMID: 33683501 PMCID: PMC8279974 DOI: 10.1007/s10637-020-01056-4

Abstract

BI 836826 is a chimeric immunoglobulin G1 antibody targeting CD37, a transmembrane protein expressed on normal and malignant B cells. This open-label, phase Ib, dose-escalation study was conducted to determine the recommended phase II dose (RP2D) of BI 836826 + ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia (CLL). Eligible patients received 420 mg/day of ibrutinib with escalating doses of BI 836826. BI 836826 was administered in 4-week cycles. After Cycle 12, patients achieving complete response (CR), CR with incomplete marrow recovery, or minimal residual disease-negative partial response could continue to receive BI 836826 + ibrutinib every 4 weeks for ≤ 12 additional cycles. Patients received either 100 mg (n = 3) or 200 mg (n = 3) BI 836826 + ibrutinib. In the 100 mg BI 836826 cohort, one patient received two cycles and two patients received 22 cycles of BI 836826. In the 200 mg BI 836826 cohort, patients received 12, 16 and 20 cycles of BI 836826, respectively. All patients discontinued BI 836826 and continued ibrutinib outside the trial. No dose-limiting toxicities were reported in the maximum tolerated dose (MTD) evaluation period. As the trial was discontinued before the MTD was reached, the RP2D was not determined. Grade 3/4 adverse events (AEs) were predominantly hematological. Pseudomonal bacteremia was the only drug-related AE of special interest. BI 836826 + ibrutinib did not exceed the MTD at doses up to 200 mg in patients with CLL. However, RP2D and MTD were not formally established, as the sponsor discontinued the trial.

© 2021. The Author(s).

Keywords: BI 836826; CD37; Chronic lymphocytic leukemia; Phase Ib; Relapsed

References

  1. Blood. 2018 Apr 26;131(17):1910-1919 - PubMed
  2. Blood. 2019 May 9;133(19):2031-2042 - PubMed
  3. Stat Med. 1998 May 30;17(10):1103-20 - PubMed
  4. Blood. 2011 Oct 13;118(15):4159-68 - PubMed
  5. Cancers (Basel). 2019 Nov 21;11(12): - PubMed
  6. Blood. 2015 Apr 16;125(16):2497-506 - PubMed
  7. Br J Haematol. 2017 Feb;176(4):618-628 - PubMed
  8. Cancer. 2018 Aug 1;124(15):3192-3200 - PubMed
  9. Leukemia. 2020 Mar;34(3):787-798 - PubMed
  10. Blood. 1975 Aug;46(2):219-34 - PubMed
  11. Blood. 2008 Jun 15;111(12):5446-56 - PubMed
  12. N Engl J Med. 2014 Jul 17;371(3):213-23 - PubMed
  13. Blood. 2014 Feb 27;123(9):1302-8 - PubMed
  14. Leukemia. 2019 Oct;33(10):2531-2535 - PubMed
  15. Leukemia. 2014 Jul;28(7):1501-10 - PubMed
  16. Cancer Med. 2018 Apr;7(4):1043-1055 - PubMed
  17. Am J Hematol. 2019 Nov;94(11):1266-1287 - PubMed
  18. Am J Hematol. 2019 Dec;94(12):1353-1363 - PubMed
  19. Eur J Nucl Med Mol Imaging. 2019 Oct;46(11):2311-2321 - PubMed
  20. Stat Med. 2008 Jun 15;27(13):2420-39 - PubMed

Publication Types